Quad Cities Investment Group LLC Sells 1,697 Shares of Pfizer Inc. (NYSE:PFE)

Quad Cities Investment Group LLC decreased its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 7.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,487 shares of the biopharmaceutical company’s stock after selling 1,697 shares during the quarter. Quad Cities Investment Group LLC’s holdings in Pfizer were worth $569,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. GoalVest Advisory LLC lifted its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at about $32,000. VisionPoint Advisory Group LLC raised its position in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners bought a new position in Pfizer during the fourth quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new position in Pfizer during the fourth quarter worth about $37,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, June 17th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $35.86.

Check Out Our Latest Stock Analysis on Pfizer

Pfizer Stock Down 1.3 %

PFE traded down $0.37 during mid-day trading on Tuesday, reaching $27.99. 24,725,153 shares of the stock were exchanged, compared to its average volume of 41,146,926. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market capitalization of $158.61 billion, a PE ratio of -470.09, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The company has a 50 day moving average price of $27.72 and a two-hundred day moving average price of $27.70. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.37 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.